International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 10 October 2023

Page No: 2461-2467

DOI: https://doi.org/10.47191/ijmscrs/v3-i10-64, Impact Factor: 6.597

Cardiac Stress in Chronic Kidney Disease: Unraveling the Myocardial Paradox

Mario Alberto Álvarez Rodríguez[1], Ivan Alfonso Vargas Moreno[1], Héctor Adrian Gámez Alvarado[1], Valeria Fabiola Peralta Ugalde[1], Valeria Yalharaí Naif Mendoza[1], Elisa Gallegos Melgoza[2]

[1]Residente de Cardiología Clínica, Centenario Hospital Miguel Hidalgo, Secretaria de Salud, Aguascalientes, Aguascalientes.
[2]Residente de Urgencias Médico Quirúrgicas, Hospital General de Zona No. 3 IMSS, Aguascalientes, Aguascalientes.

ABSTRACT

Chronic kidney disease (CKD) represents a complex and multifaceted clinical condition characterized by its intricate interaction with multiple organ systems. Among the systemic manifestations of CKD, the impact on the cardiovascular system is particularly profound. This article delves into the intricate relationship between CKD and cardiac strain, exploring the paradoxical nature of myocardial function in the context of renal dysfunction. We navigate the epidemiological landscape, describe pathophysiological mechanisms, investigate diagnostic modalities, and explore current and emerging therapeutic strategies aimed at controlling cardiac strain in CKD. This comprehensive analysis not only sheds light on the cardiac complexities within the CKD setting, but also underscores the need for a holistic approach to improve patient outcomes.

KEYWORDS: kidney, cardiac, stress, myocardial.

ARTICLE DETAILS

Published On:
26 October 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Chronic kidney disease (CKD) represents a global health challenge of increasing magnitude affecting millions of people worldwide. Beyond its well-established impact on renal function, CKD exerts a pervasive influence on several extrarenal organ systems, with the cardiovascular system at the forefront of clinical concern. In recent years, the intricate relationship between CKD and cardiac strain has emerged as a compelling area of research and clinical interest because of the impact on mortality that cardiovascular disease still represents, 1

The paradox of cardiac strain in CKD lies in the intricate interplay between myocardial function and renal dysfunction. While CKD is associated with an increased risk of cardiovascular complications, such as hypertension, left ventricular hypertrophy, diastolic dysfunction, and heart failure, assessment of cardiac strain in this setting uncovers a more nuanced dimension. Myocardial strain, a measure of myocardial deformation, provides insight into subtle alterations in cardiac function that occur in patients with CKD, even in the absence of overt clinical symptoms.1,2

This article undertakes a comprehensive tour of the landscape of cardiac strain in CKD, beginning with an exploration of epidemiological patterns and demographic variations that underscore the clinical significance of this phenomenon. We delve into the pathophysiological mechanisms underlying cardiac strain, examining how renal dysfunction triggers a cascade of events, including volume overload, electrolyte imbalances, inflammation, oxidative stress, and neurohormonal dysregulation, all of which contribute to myocardial disturbances.2

Diagnostic assessment of cardiac strain in CKD is a focal point, with advanced imaging techniques such as echocardiography and cardiac magnetic resonance imaging (MRI) providing valuable information on myocardial deformation and function. We also investigate the role of emerging biomarkers and new diagnostic modalities to refine our ability to assess cardiac strain in patients with CKD.2,3

As we traverse the complex terrain of CKD and cardiac strain, we consider therapeutic strategies aimed at managing this myocardial paradox. From blood pressure control and volume status optimization to the potential role of renoprotective medications and lifestyle modifications, the therapeutic arsenal is expanding to address the intricate relationship between CKD and cardiac strain.3

Ultimately, this article underscores the importance of a holistic approach to the management of CKD that recognizes the intricate interplay between renal and cardiac function. By

unraveling the mysteries of cardiac strain in CKD, we aim to provide clinicians and researchers with valuable insights that can inform clinical decision making, improve patient care, and pave the way for innovative strategies to improve the prognosis and quality of life for people going through the disease. The complex intersection between CKD and cardiac health.4

Prevalence of cardiac strain in CKD:

Epidemiological studies have consistently shown a higher prevalence of cardiac stress in patients with CKD compared to the general population. In addition, the main cause of mortality in patients with CKD is cardiovascular causes, especially in hemodialysis. Cardiovascular mortality has even been described to be 10 to 20 times more frequent in these patients than in the general population. 5,6

The degree of myocardial deformation varies according to the different stages of CKD, with a clear upward trend as renal function decreases. This association underscores the importance of renal function assessment in the evaluation of cardiac health.7

Risk factors:

Understanding the risk factors for cardiac strain in CKD is crucial for early detection and intervention. Hypertension, a common comorbidity in CKD, plays a key role in the development of cardiac strain. Classical cardiovascular risk factors do not fully explain the large cardiovascular risk in these patients. In addition to ischemia, electrolyte imbalances, such as hyperkalemia and hyperphosphatemia, are recognized to contribute, as well as uremia, anemia, water retention. Proteinuria, characteristic of CKD, is another risk factor that deserves attention in epidemiological investigations.7

Clinical implications:

Cardiac strain in CKD has profound clinical implications, including increased morbidity and mortality rates. Patients with CKD and cardiac strain are at increased risk for adverse cardiovascular events, ischemic heart disease, valvular heart disease, arrhythmias, heart failure, and sudden cardiac death. Consequently, epidemiological research on this phenomenon serves as a basis for risk stratification, early intervention strategies, and the development of personalized treatment approaches.7

The epidemiology of cardiac strain in chronic kidney disease is a complex and multifaceted field of study. Through rigorous epidemiological investigations, we can gain a deeper understanding of the prevalence, risk factors, and clinical consequences of cardiac strain in patients with CKD. This knowledge can guide health care professionals to identify individuals at risk and implement timely interventions, ultimately improving the management and outcomes of CKD patients with cardiac strain. As research in this area continues to evolve, it holds promise for improving the quality of care and prolonging the lives of people affected by this challenging comorbidity.7

Pathophysiology of cardiac strain in chronic kidney disease.

Chronic kidney disease, a progressive renal disorder, has become a formidable global health challenge. Beyond its primary impact on renal function, CKD exerts profound effects on the cardiovascular system, often resulting in structural and functional abnormalities, including cardiac strain. This article provides an exploration of the pathophysiological complexities that cause cardiac strain in the context of CKD.7

Renal-cardiac axis:

The pathophysiological relationship between CKD and cardiac stress is rooted in the intricate interaction between the kidneys and the heart, often referred to as the "cardiorenal axis". Reduced renal function in CKD leads to accumulation of uremic toxins, electrolyte imbalances, and fluid retention. These alterations set the stage for a cascade of events that adversely affect the myocardium and vice versa, termed the "cardiorenal syndrome" by Silverberg.6,7

Hemodynamic changes:

The progressive loss of renal function in CKD contributes to volume overload and increased systemic vascular resistance. These hemodynamic alterations lead to elevated blood pressure, which exacerbates the workload of the heart. Chronic hypertension, a common comorbidity in CKD, places additional stress on cardiac muscle, promoting hypertrophy and fibrosis. Often this overload results from atherosclerosis or aortic stenosis.7

Uremic toxins and inflammation:

Retention of uremic toxins in patients with CKD contributes to a state of chronic inflammation. Elevated levels of proinflammatory cytokines and oxidative stress alter normal cardiac cell function and promote myocardial fibrosis. This inflammatory environment further contributes to cardiac stress and dysfunction. The pathophysiology of uremia-induced transformations in the left ventricular chamber is complex and multifactorial.7

Electrolyte imbalances:

Electrolyte imbalances, such as hyperkalemia and hyperphosphatemia, are frequent in CKD. These alterations have direct toxic effects on cardiac myocytes, altering their contractility and electrical conduction. Dysregulated electrolytes also alter the delicate balance of calcium ions, essential for normal myocardial function. On the other hand, secondary hyperparathyroidism promotes myocardial, valvular and vascular calcification 8

Activation of the renin-angiotensin-aldosterone system (RAAS):

In CKD, overactivation of the RAAS system plays a key role in cardiac stress. Angiotensin II, a potent vasoconstrictor, promotes cardiac remodeling and fibrosis, further compromising cardiac function. The aldosterone system, in response to electrolyte imbalances, exacerbates sodium and water retention, perpetuating volume overload. The pathophysiology of cardiac strain in chronic kidney disease is a multifaceted process, driven by a complex interplay of factors including hemodynamic changes, uremic toxins,

inflammation. The pathophysiology of cardiac strain in CKD is a multifaceted process, driven by a complex interaction of factors including hemodynamic changes, uremic toxins, inflammation, electrolyte imbalances and activation of the renin-angiotensin-aldosterone system. 8

A thorough understanding of these mechanisms is critical to guide therapeutic strategies aimed at mitigating cardiac strain in patients with CKD. As research continues to unravel the complexities of this relationship, new targeted interventions may emerge that ultimately improve the treatment and prognosis of CKD patients at risk for cardiac strain.8,9,10

Clinical manifestations of cardiac strain in chronic kidney disease.

Chronic kidney disease (CKD) represents a multifaceted medical condition, closely related to various cardiovascular complications, particularly cardiac stress. This article elucidates the complex clinical presentations and manifestations associated with cardiac strain in the context of CKD. Through a thorough exploration of clinical observations and relevant medical studies, we aim to provide a comprehensive overview of the myriad clinical challenges posed by this complex interaction.10

Hypertension and cardiovascular disorders:

One of the hallmark clinical manifestations of cardiac strain in CKD is hypertension, which is often difficult to control. This hypertensive state imposes an excessive workload on the heart, resulting in left ventricular hypertrophy and diastolic dysfunction, by consequent cell death and myocardial fibrosis. These cardiovascular disorders can lead to dilatation and further compensatory hypertrophy leading to heart failure, a prevalent clinical consequence in patients with CKD.11

Heart failure and its subtypes:

Cardiac stress frequently precipitates heart failure, which can manifest as systolic or diastolic dysfunction. In systolic heart failure, the heart's ability to pump blood is compromised, resulting in symptoms such as dyspnea, fatigue, and reduced exercise tolerance. Diastolic heart failure, on the other hand, is characterized by impaired ventricular relaxation, resulting in symptoms similar to those of systolic heart failure The development of heart failure is influenced by hypertension and ventricular hypertrophy, neurohormonal activation, accelerated ischemia, and a vicious cycle of renal interaction; heart failure can lead to prerenal uremia, which in turn promotes cardiac damage. 12

Arrhythmias and conduction abnormalities:

Electrolyte imbalances, a common occurrence in CKD, coupled with metabolic disturbances, neurohumoral activation, fibrosis, and increased electrical excitability, significantly elevate the risk of arrhythmias. Patients with CKD may present with atrial fibrillation, ventricular arrhythmias or conduction abnormalities, which may further impair cardiac function and increase the risk of adverse cardiovascular events.12

Sudden cardiac death:

The intricate interplay of factors such as electrolyte imbalances, structural cardiac abnormalities, and arrhythmias in patients with CKD places them at increased risk for sudden cardiac death. Early identification of high-risk individuals and intervention are imperative to mitigate this potentially fatal complication.12

Chest pain and ischemic heart disease:

Patients with CKD may experience atypical chest pain, often associated with hypertension and frequently related to ischemic heart disease. The coexistence of CKD and atherosclerosis increases the risk of myocardial infarction. Therefore, careful surveillance and preventive measures are crucial in this patient population.12

Peripheral edema and fluid overload:

Patients with CKD often suffer from fluid retention, culminating in peripheral edema and pulmonary congestion. Clinical manifestations of fluid overload include lower extremity edema, jugular venous distention, and crackles on auscultation. As myocardial strain increases the LV pressure-volume curve shifts to the left, i.e., small increases in volume can trigger significant pressure elevations, manifested by congestive heart failure and pulmonary edema. 13,14,15

Valvulopathies

Calcification of cardiac valves is frequent in patients with CKD, particularly in dialysis, due to alterations in calcium and phosphorus metabolism, and accelerated aging. The role of chronic inflation has also been proposed. 24 The most affected valves are mitral and aortic, which can contribute to increased LV volume and pressure, and myocardial tension, while atrial and ventricular dilatation cause mitral and tricuspid insufficiency that further increase overload and heart failure.

The clinical manifestations of cardiac strain in CKD span a broad spectrum, from hypertension, heart failure, and arrhythmias to sudden cardiac death, chest pain, and fluid overload. Recognizing and addressing these manifestations is of paramount importance to optimize the care and treatment of patients with CKD. A multidisciplinary approach that addresses both renal and cardiac aspects is essential to mitigate the significant cardiovascular burden imposed by this intricate interaction. Effective management strategies should be implemented to improve the outcomes and quality of life of CKD patients facing cardiac stress.12

Diagnosis of cardiac stress in chronic renal disease

Clinical evaluation:

History and physical examination: The initial step in diagnosing cardiac strain in CKD involves a thorough medical history and physical examination. Key clinical indicators may include hypertension, often difficult to control, symptoms of heart failure (dyspnea, fatigue, edema), arrhythmias, and atypical chest pain.12

Blood pressure monitoring: hypertension is a common comorbidity in CKD, whether primary or secondary, and can be an early sign of cardiac strain. Ambulatory blood pressure

monitoring can provide valuable information on blood pressure patterns, including nocturnal hypertension.13

Image modalities:

Echocardiography: Echocardiography is a cornerstone in the diagnosis of cardiac strain. It can assess cardiac chamber dimensions, left ventricular mass, ejection fraction, diastolic function, and evaluate structural abnormalities such as hypertrophy, dilatation, and valvular and pericardial pathologies.13It has been found that in patients with CKD on hemodialysis, only 16% had normal echocardiograms.21 Hypertrophy increases the risk of sudden death and LV systolic dysfunction is a powerful indicator of unfavorable prognosis for patients both on hemodialysis and after renal transplantation. On the other hand, diastolic dysfunction has been identified in up to 50% to 60% of patients with CKD. Evaluation of increased left atrial volume can identify a higher risk of heart failure, atrial arrhythmias and poor clinical outcome. 14

Cardiac magnetic resonance imaging: cardiac magnetic resonance imaging (MRI) provides high-resolution images and can provide detailed information on myocardial function, tissue characterization and fibrosis, which are critical for diagnosing cardiac strain.15

Computed tomography angiography: in some cases, coronary computed tomography angiography may be indicated to evaluate coronary artery disease, a significant contributor to cardiac stress.15

Biomarkers: brain natriuretic peptide (BNP) and N-terminal pro B-type natriuretic peptide (NT-proBNP): Their increase is due to a response to myocardial wall stretch, to induce vasodilatation, natriuresis and diuresis. In patients with decreased renal function and on dialysis, NT-proBNP levels increase, partly due to decreased excretion. But even so, NT-proBNP correlates with impaired cardiac function and volume overload. elevated BNP and NT-proBNP levels are indicative of cardiac stress and heart failure and can aid in diagnosis and risk stratification.16,17

Troponin: elevated cardiac troponin levels may suggest myocardial injury and are relevant in the context of ischemic heart disease.17

Electrocardiography (ECG): routine ECG may reveal arrhythmias, conduction abnormalities, left ventricular hypertrophy and other electrocardiographic signs of cardiac strain. Of special note is QRS fragmentation, which has been correlated with regional LV systolic dysfunction, assessed by longitudinal global strain (GLS), in the presence of normal ejection fraction. 18,19

Emerging technologies:

Strain imaging: speckle tracking echocardiography and cardiac strain imaging techniques offer advanced assessment of myocardial deformation, providing valuable information on subtle changes in cardiac function. Global longitudinal strain is an accurate tool for detecting subclinical LV systolic dysfunction, in patients with various stages of renal disease, dialysis and even post-transplant. 20,21

Metabolomics and proteomics: cutting-edge approaches in metabolomics and proteomics may uncover new biomarkers and pathways associated with cardiac strain in CKD, improving diagnostic accuracy.15

The diagnosis of cardiac strain in chronic kidney disease requires a multidimensional approach encompassing clinical assessment, advanced imaging modalities, biomarkers, and emerging technologies. Early detection and accurate assessment of cardiac strain are critical to facilitate timely intervention and optimize treatment of CKD patients facing this complex comorbidity. Ongoing research and technological advances continue to refine our diagnostic capabilities, promising improved outcomes for CKD patients at risk for cardiac strain. 14

Treatment of cardiac stress in chronic kidney disease

Chronic kidney disease (CKD) is intrinsically linked to a spectrum of cardiovascular complications, with cardiac strain being a major concern. This article is introduced to the multifaceted treatment landscape of cardiac strain in CKD and provides a comprehensive overview of therapeutic strategies, including lifestyle modifications, pharmacological interventions, and emerging therapies. By addressing the intricacies of managing this complex comorbidity, our goal is to improve the care and prognosis of patients with CKD affected by cardiac strain.14

CKD, characterized by progressive renal dysfunction, has far-reaching cardiovascular implications, most notably cardiac stress. Effective management of cardiac stress is imperative to improve clinical outcomes and quality of life in patients with CKD.

Lifestyle modifications:

Blood pressure control: control of hypertension is paramount. Lifestyle modifications, including dietary sodium restriction, weight loss, and increased physical activity, play a key role in blood pressure control. Antihypertensive medications, such as ACE inhibitors and angiotensin receptor blockers (ARBs), are commonly used in patients with CKD to relieve cardiac stress.15

Dietary interventions: dietary changes, such as adherence to a heart-healthy diet low in saturated fat, cholesterol, and refined sugars, can help mitigate cardiac stress. 15

Fluid restriction: controlling fluid intake is essential in patients with CKD to prevent fluid overload and the resulting strain on the heart.15

Pharmacological interventions:

Diuretics: loop diuretics, such as furosemide, are often prescribed to control fluid overload in patients with CKD, thereby reducing cardiac pressure. Thiazide diuretics may also be considered, particularly in those with concomitant hypertension. 16

Antihypertensive medications: ACE inhibitors, ARBs, beta-blockers and calcium channel blockers are essential to control hypertension and relieve cardiac stress. The choice of medication depends on the patient's specific clinical profile16.

Management of mineral and bone disorders (CKD-MBD): in cases of secondary hyperparathyroidism, drugs such as calcimimetics (cinacalcet) or vitamin D analogues can be used to maintain mineral balance and reduce cardiac stress.16
Management of anemia: Erythropoiesis-stimulating agents (ESAs) can be used to treat anemia associated with CKD, thereby relieving the burden on the heart.16
Cardiac rehabilitation:
Structured cardiac rehabilitation programs, which include physical training and management of cardiovascular risk factors, can play an important role in improving cardiac function and reducing cardiac stress in patients with CKD.16
Renal replacement therapy:
In advanced stages of CKD, particularly end-stage renal disease (ESRD), renal replacement therapies such as hemodialysis or peritoneal dialysis may be necessary to control fluid and electrolyte imbalances, thereby mitigating cardiac stress.16
Emerging therapies:
New antifibrotic agents: research is underway for the development of antifibrotic agents targeting myocardial fibrosis, which is a common component of cardiac strain in CKD.16
Metabolic modulators: emerging therapies aimed at modulating metabolic pathways involved in cardiac strain hold promise for future treatment.16
The treatment of cardiac strain in chronic kidney disease is a multifaceted effort that requires a holistic approach encompassing lifestyle modifications, pharmacological interventions, and, in advanced cases, renal replacement therapy. Effective cardiac stress management is critical to improving cardiovascular outcomes in patients with CKD and improving their overall quality of life. Ongoing research into emerging therapies has the potential to revolutionize the treatment landscape, offering new avenues to improve the prognosis of CKD patients facing this complex comorbidity.16

CONCLUSION

Chronic kidney disease (CKD) is a systemic condition that extends its influence far beyond the boundaries of renal dysfunction and profoundly affects the cardiovascular system. Among the myriad cardiovascular complications faced by patients with CKD, cardiac stress stands out as a formidable adversary. This complex interplay between CKD and cardiac strain underscores the intricate nature of this multifaceted comorbidity.
Understanding the nuanced relationship between CKD and cardiac strain is essential to improve patient outcomes and enhance quality of care. It is clear that cardiac strain in CKD is not a solitary entity but rather a convergence of multifactorial determinants. These determinants range from hemodynamic changes and electrolyte imbalances to uremic toxins, inflammation, and structural cardiac abnormalities. The clinical manifestations, diagnostic challenges and therapeutic considerations associated with this condition reflect its intricate pathophysiology.24
In terms of clinical manifestations, patients with CKD may present with hypertension, heart failure, arrhythmias, chest pain, and peripheral edema, all of which are manifestations of cardiac stress. Early recognition and intervention of these clinical signs are critical to avoid adverse cardiovascular events and improve patient outcomes.25
The diagnostic landscape is equally complex and requires a multifaceted approach incorporating clinical assessment, imaging modalities, biomarkers, and emerging technologies. Echocardiography, cardiac magnetic resonance imaging, and biomarkers such as BNP and NT-proBNP are indispensable tools for identifying and assessing cardiac strain in patients with CKD. Emerging technologies, such as strain imaging and advanced metabolomics, promise to further refine our diagnostic capabilities.25
Treatment strategies encompass a comprehensive approach that includes lifestyle modifications, pharmacological interventions and, in advanced cases, renal replacement therapy. Blood pressure control, dietary interventions, and fluid restriction are critical components of lifestyle modifications. Pharmacological interventions often include antihypertensive medications, diuretics, and therapies aimed at controlling mineral and bone disorders or anemia. Cardiac rehabilitation programs and renal replacement therapies play a vital role in optimizing cardiac health in patients with CKD. 26
In conclusion, cardiac strain in CKD is a multifaceted and challenging comorbidity that requires a holistic approach to diagnosis and treatment. With ongoing research, emerging therapies, and a deeper understanding of the pathophysiology involved, there is hope for better outcomes and improved quality of life for CKD patients dealing with the complexities of cardiac strain. A collaborative effort between nephrologists, cardiologists, and other health care professionals is essential to address this intricate interplay and improve the care of patients with CKD. 26

REFERENCES

I. Bright R. Cases and observations, illustrative of renal disease, accompanied with the secretion of albuminous urine. Guy's Hosp Trans. 1836338–379
II. Stevens PE, O'Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, Hague N, New J, Farmer CK. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72:92–99. doi: 10.1038/sj.ki.5002273
III. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, Tonelli M; Alberta Kidney Disease Network. Cause of death in patients with reduced kidney function. J Am Soc Nephrol. 2015;26:2504–2511. doi: 10.1681/ASN.2014070714

IV. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389:1238–1252. doi: 10.1016/S0140-6736(16)32064-5 -

V. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108: 2154-69.

VI. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32: S112-9.

VII. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;325 suppl 3S112–S119. doi: 10.1053/ajkd.1998.v32.pm9820470

VIII. Vanholder R, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, et al. . Uremic toxicity: present state of the art. Int J Artif Organs. 2001;24:695–725. doi: 10.1177/039139880102401004

IX. Kuo IY, Chapman AB. Polycystins, ADPKD, and cardiovascular disease. Kidney Int Rep. 2020;5:396–406. doi: 10.1016/j.ekir.2019.12.007

X. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266

XI. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100. doi: 10.1111/j.1523-1755.2005.00365.x

XII. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147. doi: 10.7326/0003-4819-139-2-200307150-00013

XIII. Silverberg DS, Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal disease and congestive heart failurethe cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol. 2006; 38: 295-310

XIV. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial. 2003; 16: 85-94.

XV. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150. doi: 10.1038/kisup.2012.76

XVI. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Chapter 1: definition and classification of CKD. Kidney Int Suppl (2011). 2013;3:19–62. doi: 10.1038/kisup.2012.64

XVII. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–2081. doi: 10.1016/S0140-6736(10)60674-5

XVIII. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, D'Agostino RB, Vasan RS. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969–975. doi: 10.1161/CIRCULATIONAHA.105.538132

XIX. Mulè G, Castiglia A, Cusumano C, Scaduto E, Geraci G, Altieri D, Di Natale E, Cacciatore O, Cerasola G, Cottone S. Subclinical kidney damage in hypertensive patients: a renal window opened on the cardiovascular system. Focus on microalbuminuria. Adv Exp Med Biol. 2017;956:279–306. doi: 10.1007/5584_2016_85

XX. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28. doi: 10.1038/ki.2010.483

XXI. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996; 49: 1428-34.

XXII. McGregor E, Jardine AG, Murray LS, Dargie HJ, Rodger RS, Junor BJ, et al. Preoperative echocardiographic abnormalities and adverse outcome following renal transplantation. Nephrol Dial Transplant. 1998; 13: 1499-505.

XXIII. Kunz K, Dimitrov Y, Muller S, Chantrel F, Hannedouche T. Uraemic cardiomyopathy. Nephrol Dial Transplant. 1998; 13 (Suppl 4): 39-43.

XXIV. Wang AY, Woo J, Wang M, Sea MM, Ip R, Li PK, et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol. 2001; 12: 1927-36.

XXV. 15. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357-2368. doi: 10.1016/j.jacc.2007.09.021.

XXVI. Nikoo MH, Jamali Z, Razeghian-Jahromi I, Sayadi M, Verdecchia P, Abtahi F. Fragmented QRS as an early predictor of left ventricular systolic dysfunction in healthy individuals: a nested case-control study in the era of speckle tracking echocardiography. Cardiovasc Ultrasound. 2020 Aug 13;18(1):33. doi: 10.1186/s12947-020-00216-z. PMID: 32791984; PMCID: PMC7427061.